Stocktoria
Indaptus Therapeutics, Inc. INDP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-09-07
Indaptus Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $9.3M | $7.3M | $7.6M | $6.3M | $2.5M |
| Operating income | -$19.8M | -$15.4M | -$16.4M | -$14.9M | -$7.7M |
| Income tax | $1,716 | $1,700 | $2,450 | $30 | $1,650 |
| Net income | -$20.8M | -$15.0M | -$15.4M | -$14.3M | -$7.7M |
| EPS (diluted) | $-21.58 | $-44.96 | $-1.83 | $-1.73 | — |
| Operating cash flow | -$14.8M | -$12.3M | -$13.4M | -$13.1M | -$11.3M |
| Free cash flow | — | — | — | — | -$11.3M |
| Cash & equivalents | $8.5M | $5.8M | $13.4M | $9.6M | $39.1M |
| Total assets | $9.3M | $7.3M | $14.9M | $28.1M | $40.6M |
| Total liabilities | — | $3.4M | $2.8M | $3.4M | $4.7M |
| Shareholders' equity | $3.2M | $3.9M | $12.1M | $24.6M | $35.9M |
Source: SEC EDGAR filings · CIK 0001857044 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.